Sacubitril/Valsartan Initiation Among Veterans Who Are Renin‐Angiotensin‐Aldosterone System Inhibitor Naïve With Heart Failure and Reduced Ejection Fraction

BACKGROUND: Sacubitril/valsartan, a first‐in‐class angiotensin receptor neprilysin inhibitor, received US Food and Drug Administration approval in 2015 for heart failure with reduced ejection fraction (HFrEF). Our objective was to describe the sacubitril/valsartan initiation rate, associated charact...

Descripción completa

Detalles Bibliográficos
Autores principales: Mohanty, April F., Levitan, Emily B., King, Jordan B., Dodson, John A., Vardeny, Orly, Cook, James, Herrick, Jennifer S., He, Tao, Patterson, Olga V., Alba, Patrick R., Russo, Patricia A., Obi, Engels N., Choi, Michelle E., Fang, James C., Bress, Adam P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8751890/
https://www.ncbi.nlm.nih.gov/pubmed/34612065
http://dx.doi.org/10.1161/JAHA.120.020474

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8751890/
https://www.ncbi.nlm.nih.gov/pubmed/34612065
http://dx.doi.org/10.1161/JAHA.120.020474

Ejemplares similares